{# ── Billing problem banner: payment failed (past_due) or retries exhausted (unpaid). Pro access is gated off by is_pro until the card is fixed, so prompt the user to update billing. ── #}

Red Flags Detected

  • Restatement (new) — Company must restate Q1 2026 financials due to revenue recognition errors totaling $529K.
  • Material Weakness (new) — Internal control deficiency over customer purchase order evaluation led to premature revenue recognition.
NASDAQ: NMTC NEUROONE MEDICAL TECHNOLOGIES Corp 8-K

NeuroOne to restate Q1 2026 results after $529K revenue overstatement from control failures

Filed May 22, 2026 · Period ending May 21, 2026 · ~1 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade NMTC commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Feedback
View original filing on SEC.gov

Generated by AI · May 25, 2026 10:05 PM